TY - JOUR
T1 - Progress report on new antiepileptic drugs
T2 - A summary of the Eigth Eilat Conference (EILAT VIII)
AU - Bialer, Meir
AU - Johannessen, Svein I.
AU - Kupferberg, Harvey J.
AU - Levy, René H.
AU - Perucca, Emilio
AU - Tomson, Torbjörn
PY - 2007/1
Y1 - 2007/1
N2 - The Eigth Eilat Conference on New Antiepileptic Drugs (AEDs)-EILAT VII, took place in Sitges, Barcelona from the 10th to 14th September, 2006. Basic scientists, clinical pharmacologists and neurologists from 24 countries attended the conference, whose main themes included a focus on status epilepticus (epidemiology, current and future treatments), evidence-based treatment guidelines and the potential of neurostimulation in refractory epilepsy. Consistent with previous formats of this conference, the central part of the conference was devoted to a review of AEDs in development, as well as updates on marketed AEDs introduced since 1989. This article summarizes the information presented on drugs in development, including brivaracetam, eslicarbazepine acetate (BIA-2-093), fluorofelbamate, ganaxolone, huperzine, lacosamide, retigabine, rufinamide, seletracetam, stiripentol, talampanel, valrocemide, JZP-4, NS1209, PID and RWJ-333369. Updates on felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine and new extended release oxcarbazepine formulations, pregabalin, tiagabine, topiramate, vigabatrin, zonisamide and new extended release valproic acid formulations, and the antiepileptic vagal stimulator device are also presented.
AB - The Eigth Eilat Conference on New Antiepileptic Drugs (AEDs)-EILAT VII, took place in Sitges, Barcelona from the 10th to 14th September, 2006. Basic scientists, clinical pharmacologists and neurologists from 24 countries attended the conference, whose main themes included a focus on status epilepticus (epidemiology, current and future treatments), evidence-based treatment guidelines and the potential of neurostimulation in refractory epilepsy. Consistent with previous formats of this conference, the central part of the conference was devoted to a review of AEDs in development, as well as updates on marketed AEDs introduced since 1989. This article summarizes the information presented on drugs in development, including brivaracetam, eslicarbazepine acetate (BIA-2-093), fluorofelbamate, ganaxolone, huperzine, lacosamide, retigabine, rufinamide, seletracetam, stiripentol, talampanel, valrocemide, JZP-4, NS1209, PID and RWJ-333369. Updates on felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine and new extended release oxcarbazepine formulations, pregabalin, tiagabine, topiramate, vigabatrin, zonisamide and new extended release valproic acid formulations, and the antiepileptic vagal stimulator device are also presented.
KW - Antiepileptic drugs
KW - Clinical trials
KW - Conference
KW - Drug development
KW - Epilepsy
KW - Pharmacology
UR - http://www.scopus.com/inward/record.url?scp=33846194013&partnerID=8YFLogxK
U2 - 10.1016/j.eplepsyres.2006.10.008
DO - 10.1016/j.eplepsyres.2006.10.008
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 17158031
AN - SCOPUS:33846194013
SN - 0920-1211
VL - 73
SP - 1
EP - 52
JO - Epilepsy Research
JF - Epilepsy Research
IS - 1
ER -